Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells-Reference-Cited by-同舟云学术

Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells

Author:

Ni Jie¹,Zhou Lei-lei²,Ding Li³,Zhang Xue-qin⁴,Zhao Xia⁵,Li Huizi¹,Cao Haixia¹,Liu Siwen¹,Wang Zhuo¹,Ma Rong¹,Wu Jianzhong¹,Feng Jifeng¹^ORCID

Affiliation:

1. Nanjing Medical University Affiliated Cancer Hospital; Jiangsu Cancer Hospital; Jiangsu Institute of Cancer Research; Nanjing Jiangsu 210000 China

2. Department of Oncology; Huai'an First People's Hospital; Nanjing Medical University; Huai'an Jiangsu China

3. The Jiangsu Province Research Institute for Clinical Medicine; The First Affiliated Hospital with Nanjing Medical University; Nanjing 210029 China

4. Hebei Provincial Children's Hospital; Hebei China

5. Department of Oncology; First People's Hospital of Yancheng; Fourth Affiliated Hospital of Nantong University; Yancheng 224001 China

Funder

The National Nature Science Foundation of China

Natural Science Foundation of Jiangsu Province

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference33 articles.

1. Cancer statistics in China, 2015;Chen;CA Cancer J. Clin.,2016a

2. Cancer statistics, 2016;Siegel;CA Cancer J. Clin.,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献